`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`__________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________
`
`REGENERON PHARMACEUTICALS, INC.,
`Petitioner
`v.
`
`NOVARTIS PHARMA AG,
`NOVARTIS TECHNOLOGY LLC,
`NOVARTIS PHARMACEUTICALS CORPORATION,
`Patent Owners
`
`__________
`
`Case IPR2021-00816
`U.S. Patent No. 9,220,631
`
`__________
`
`PATENT OWNER’S NOTICE OF WITHDRAWAL OF
`ITS CONTINGENT MOTION TO AMEND
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`On January 18, 2022, Patent Owner filed a Contingent Motion to Amend in
`
`IPR2021-00816
`U.S. Patent No. 9,220,631
`
`
`this proceeding. Paper 37. On April 15, 2022, Petitioner filed an Opposition to
`
`that Motion. Paper 74. On May 12, 2022, the Board issued its Preliminary
`
`Guidance regarding Patent Owner’s Motion to Amend. Paper 87. Pursuant to the
`
`Board’s Pilot Program Concerning Motion to Amend Practice and Procedures, 84
`
`Fed. Reg. 9,497, 9,502 (Mar. 15, 2019), Patent Owner hereby withdraws its
`
`Contingent Motion to Amend. Patent Owner reserves all rights, remedies and
`
`defenses with respect to the issued claims of U.S. Patent No. 9,220,631.
`
`Dated: May 26, 2022
`
`
`
`
`Dated: May 26, 2022
`
`
`Respectfully submitted,
`
`By: /Elizabeth J. Holland/
`Elizabeth J. Holland (Reg. No. 47,657)
`(for filing credentials only)
`Allen & Overy LLP
`1221 Avenue of the Americas
`New York, NY 10020
`Phone: (212) 61--6365
`Elizabeth.holland@allenovery.com
`
`Respectfully submitted,
`
`By: /Nicholas K. Mitrokostas/
`Nicholas K. Mitrokostas (pro hac vice
`granted)
`Back-up Counsel for Patent Owners
`Allen & Overy LLP
`One Beacon Street
`Boston, Massachusetts 02108
`Phone: (857) 353-4500
`Fax: (857) 353-4599
`Nicholas.Mitrokostas@allenovery.com
`
`1
`
`
`
`IPR2021-00816
`U.S. Patent No. 9,220,631
`
`
`
`CERTIFICATE OF SERVICE
`
`A copy of this Patent Owners’ Notice of Withdrawal of Its Contingent
`
`Motion to Amend has been served on Petitioner’s attorneys of record as follows
`
`via electronic mail:
`
`
`
`
`
`
`
`Elizabeth Stotland Weiswasser (Reg. No. 55,721)
`Anish R. Desai (Reg. No. 73,760)
`Natalie Kennedy (Reg. No. 68,511)
`Andrew Gesior (Reg. No. 76,588)
`Weil, Gotshal & Manges LLP
`767 Fifth Avenue
`New York, NY 10153
`T: 212-310-8022
`elizabeth.weiswasser@weil.com
`anish.desai@weil.com
`natalie.kennedy@weil.com
`andrew.gesior@weil.com
`
`Brian E. Ferguson (Reg. No. 36,801)
`Christopher M. Pepe (Reg. No. 73,851)
`Weil, Gotshal & Manges LLP
`2001 M Street, N.W., Suite 600
`Washington, D.C. 20036
`T: 202-682-7000
`brian.ferguson@weil.com
`christopher.pepe@weil.com
`Regeneron.IPR.Service@weil.com
`
`Attorneys for Regeneron Pharmaceuticals, Inc.
`
`
`
`
`
`
`
`
`
`
`
`
`Dated: May 26, 2022
`
`
`IPR2021-00816
`U.S. Patent No. 9,220,631
`
`By: /Frank ReDavid/
`Frank ReDavid
`Litigation Specialist
`Allen & Overy LLP
`
`
`
`
`
`
`
`
`
`